Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver

References

• Knell AJ. Liver function and failure: the evolution of liver physiology. J R Coll Physicians Lond. 1980;14(3):205–208.
   PubMedGoogle Scholar
• Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177–197.
   PubMed Web of Science ®Google Scholar
• Tarasenko TN, McGuire PJ. The liver is a metabolic and immunologic organ: A reconsideration of metabolic decompensation due to infection in inborn errors of metabolism (IEM). Mol Genet Metab. 2017;121(4):283–288.
   PubMed Web of Science ®Google Scholar
• Gordillo M, Evans T, Gouon-Evans V. Orchestrating liver development. Development. 2015;142(12):2094–2108.
   PubMed Web of Science ®Google Scholar
• Koo SH. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol. 2013;19(3):210–215.
   PubMedGoogle Scholar
• Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13(3):267–276.
   PubMed Web of Science ®Google Scholar
• Preziosi ME, Monga SP. Update on the mechanisms of liver regeneration. Semin Liver Dis. 2017;37(2):141–151.
   PubMed Web of Science ®Google Scholar
• Aguilera-Méndez A, Álvarez-Delgado C, Hernández-Godinez D, et al., Hepatic diseases related to triglyceride metabolism. Mini Rev Med Chem. 2013;13(12): 1691–1699.
   PubMed Web of Science ®Google Scholar
• Forbes S, Vig P, Poulsom R, et al. Hepatic stem cells. J Pathol. 2002;197(4):510–518.
   PubMed Web of Science ®Google Scholar
• Overi D, Carpino G, Cardinale V, et al. Contribution of resident stem cells to liver and biliary tree regeneration in human diseases. Int J Mol Sci. 2018;19(10):2917.
   Web of Science ®Google Scholar
• The top 10 causes of death. 2018. [cited 2020 May 3]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death
   Google Scholar
• Zhao J, Zhang Z, Luan Y, et al. Pathological functions of interleukin-22 in chronic liver inflammation and fibrosis with hepatitis B virus infection by promoting T helper 17 cell recruitment. Hepatology. 2014;59(4):1331–1342.
   PubMed Web of Science ®Google Scholar
• Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis. 2015;35(2):146–156.
   PubMed Web of Science ®Google Scholar
• Wallace MC, Friedman SL, Mann DA. Emerging and disease-specific mechanisms of hepatic stellate cell activation. Semin Liver Dis. 2015;35(2):107–118.
   PubMed Web of Science ®Google Scholar
• Wallace MC, Friedman SL. Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development. Gene Expr. 2014;16(2):77–84.
   PubMed Web of Science ®Google Scholar
• Raza S, Rajak S, Anjum B, et al. Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma. Hepatoma Res. 2019;5:42.
   PubMedGoogle Scholar
• Mantovani A, Scorletti E, Mosca A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020; 154170. DOI:10.1016/j.metabol.2020.154170
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82–97.
   PubMed Web of Science ®Google Scholar
• Hui E, Xu A, Bo Yang H, et al. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J Diabetes Investig. 2013;4(5):413–425.
   PubMed Web of Science ®Google Scholar
• Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol. 2014;20(44):16452–16463.
   PubMed Web of Science ®Google Scholar
• Corey KE, Kaplan LM. Obesity and liver disease: the epidemic of the twenty-first century. Clin Liver Dis. 2014;18(1):1–18.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
   PubMed Web of Science ®Google Scholar
• Barros BSV, Santos DC, Pizarro MH, et al. Type 1 diabetes and non-alcoholic fatty liver disease: when should we be concerned? A nationwide study in Brazil. Nutrients. 2017;9(8):878.
   Web of Science ®Google Scholar
• Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38(1):47–51.
   PubMedGoogle Scholar
• Anania C, Perla FM, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24(19):2083–2094.
   PubMed Web of Science ®Google Scholar
• Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the united states. Gastroenterology. 2015;148(3):547–555.
   PubMed Web of Science ®Google Scholar
• Marroni CA, Jr AM F, Fernandes SA, et al. Liver transplantation and alcoholic liver disease: history, controversies, and considerations. World J Gastroenterol. 2018;24(26):2785–2805.
   PubMed Web of Science ®Google Scholar
• Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–438.
   PubMed Web of Science ®Google Scholar
• Ikura Y. Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades. World J Hepatol. 2014;6(12):894–900.
   PubMedGoogle Scholar
• Ferramosca A, Zara V. Modulation of hepatic steatosis by dietary fatty acids. World J Gastroenterol. 2014;20(7):1746–1755.
   PubMed Web of Science ®Google Scholar
• Enomoto H, Bando Y, Nakamura H, et al. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(24):7427–7435.
   PubMed Web of Science ®Google Scholar
• Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39(1):328–348.
   PubMed Web of Science ®Google Scholar
• Stevanović J, Beleza J, Coxito P, et al. Physical exercise and liver “fitness”: role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease. Mol Metabol. 2019;32:1–14.
   PubMed Web of Science ®Google Scholar
• Wobser H, Dorn C, Weiss TS, et al. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19(8):996–1005.
   PubMed Web of Science ®Google Scholar
• Lakshman R, Shah R, Reyes-Gordillo K, et al. Synergy between NAFLD and AFLD and potential biomarkers. Clin Res Hepatol Gastroenterol. 2015;39(1):S29–34.
   PubMedGoogle Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci. 2014;15(6):9924–9944.
   PubMed Web of Science ®Google Scholar
• Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048.
   PubMed Web of Science ®Google Scholar
• Fang Y, Chai Z, Wang D, et al. DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway. Mol Cell Biochem. 2015;399(1–2):269–278.
   PubMed Web of Science ®Google Scholar
• Conjeevaram Selvakumar PK, Kabbany MN, Alkhouri N. Nonalcoholic fatty liver disease in children: not a small matter. Paediatr Drugs. 2018;20(4):315–329.
   PubMed Web of Science ®Google Scholar
• Rosso N, Chavez-Tapia NC, Tiribelli C, et al. Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol. 2014;20(27):9038–9049.
   PubMed Web of Science ®Google Scholar
• Pais R, Barritt AS, Calmus Y, et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol. 2016;65(6):1245–1257.
   PubMed Web of Science ®Google Scholar
• Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol. 2017;23(36):6549–6570.
   PubMed Web of Science ®Google Scholar
• Lãpãdat AM, Jianu IR, Ungureanu BS, et al. Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. J Med Life. 2016;10(1):19–26.
   Google Scholar
• Temple JL, Cordero P, Li J, et al. A guide to non-alcoholic fatty liver disease in childhood and adolescence. Oben Int J Mol Sci. 2016;17(6):947.
   Web of Science ®Google Scholar
• Hyysalo J, Mannisto VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol. 2014;60(4):839–846.
   PubMed Web of Science ®Google Scholar
• Sorrentino P, Tarantino G, Conca P, et al. Silent non-alcoholic fatty liver disease - a clinical-histological study. J Hepatol. 2004;41(5):751–757.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology. 2009;136(5):1585–1592.
   PubMed Web of Science ®Google Scholar
• Neuman M, Cohen L, Nanau Bsc R. Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2014;28(11):607–616.
   PubMed Web of Science ®Google Scholar
• Hernandez Roman J, Siddiqui M. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metabol. 2020:e00127.
   PubMedGoogle Scholar
• Urasaki Y, Zhang C, Cheng J, et al. Quantitative assessment of liver steatosis and affected pathways with molecular imaging and proteomic profiling. Sci Rep. 2018;8:3606.
   PubMed Web of Science ®Google Scholar
• Lovric A, Granér M, Bjornson E, et al. Characterization of diferent fat depots in NAFLD using infammation-associated proteome, lipidome and metabolome. Sci Rep. 2018;8:14200.
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–846.
   PubMed Web of Science ®Google Scholar
• Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med. 2018;91(2):147–150.
   PubMedGoogle Scholar
• Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol. 2010;2(4):139–142.
   PubMedGoogle Scholar
• Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Re. 2016;3:CD007654
   PubMedGoogle Scholar
• Mead E, Atkinson G, Richter B, et al. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database Syst Re. 2016;11:CD012436
   PubMedGoogle Scholar
• Ferreira GM, Nazar BP, da Silva MR, et al. Misuse of sibutramine and bulimia nervosa: a dangerous combination. Braz J Psychiatry. 2018;40(3):343.
   PubMedGoogle Scholar
• Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015;8(2):189–199.
   PubMed Web of Science ®Google Scholar
• Toth PP, Philip S, Hull M, et al. Elevated triglycerides (≥150 mg/dl) and high triglycerides (200–499 mg/dl) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019;15:533–538.
   PubMed Web of Science ®Google Scholar
• Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46(2):424–429.
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:b2942.
   PubMed Web of Science ®Google Scholar
• Shiffman M, Freilich B, Vuppalanchi R, et al. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;49(1):64–73.
   PubMed Web of Science ®Google Scholar
• Cao Y, Matsubara T, Zhao C, et al. Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment. Sci Rep. 2017;7:9307.
   PubMed Web of Science ®Google Scholar
• Sinha RA, Bruinstroop E, Singh BK, et al. Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists. Thyroid. 2019;29(9):1173–1191.
   PubMed Web of Science ®Google Scholar
• Silverthorn DU, Ober WC, Garrison CW, et al. Human physiology: an integrated approach. San Francisco: Pearson/Benjamin Cummings; 2010.
   Google Scholar
• Nelson DL, Cox MM. Lehninger principles of biochemistry. New York: WH Freeman; 2014.
   Google Scholar
• Moustafa T, Fickert P, Magnes C, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2012;142(1):140–151.e12.
   PubMed Web of Science ®Google Scholar
• Juárez-Hernández E, Chávez-Tapia NC, Uribe M, et al. Role of bioactive fatty acids in nonalcoholic fatty liver disease. Nutr J. 2016;15(1):72.
   PubMedGoogle Scholar
• Canbay A, Bechmann L, Gerken G. Lipid metabolism in the liver. Z Gastroenterol. 2007;45(1):35–41.
   PubMed Web of Science ®Google Scholar
• Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr. 2013;4(6):697–710.
   PubMed Web of Science ®Google Scholar
• Nassir F, Rector RS, Hammoud GM, et al. Pathogenesis and prevention of hepatic steatosis. Gastroenterol Hepatol. 2015;11(3):167–175.
   PubMedGoogle Scholar
• Perla FM, Prelati M, Lavorato M, et al. The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease. Children (Basel). 2017;4(6):46.
   PubMed Web of Science ®Google Scholar
• Jump DB, Tripathy S, Depner CM. Fatty acid-regulated transcription factors in the liver. Ann Rev Nutr. 2013;33:249–269.
   PubMed Web of Science ®Google Scholar
• Beld J, Lee DJ, Burkart MD. Fatty acid biosynthesis revisited: structure elucidation and metabolic engineering. Mol Biosyst. 2015;11(1):38–59.
   PubMedGoogle Scholar
• Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327.
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Maher JJ. Lipids in liver disease: looking beyond steatosis. Gastroenterology. 2012;142(1):8–11.
   PubMed Web of Science ®Google Scholar
• Softic S, Cohen DE, Kahn CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci. 2016;61(5):1282–1293.
   PubMed Web of Science ®Google Scholar
• Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732–749.
   PubMed Web of Science ®Google Scholar
• Ameer F, Scandiuzzi L, Hasnain S, et al. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895–902.
   PubMed Web of Science ®Google Scholar
• Jump DB. Mammalian fatty acid elongases. Methods Mol Biol. 2009;579:375–389.
   PubMedGoogle Scholar
• Park HG, Engel MG, Vogt-Lowell K, et al. The role of fatty acid desaturase (FADS) genes in oleic acid metabolism: FADS1 Δ7 desaturates 11-20:1 to 7,11-20:2. Prostaglandins Leukot Essent Fatty Acids. 2018;128:21–25.
   PubMed Web of Science ®Google Scholar
• Nguyen P, Leray V, Diez M, et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl). 2008;92(3):272–283.
   PubMed Web of Science ®Google Scholar
• Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab. 2008;34(6 Pt 2):643–648.
   PubMed Web of Science ®Google Scholar
• Mouzat K, Chudinova A, Polge A, et al. Regulation of brain cholesterol: what role do liver x receptors play in neurodegenerative diseases? Int J Mol Sci. 2019;20(16):3858.
   Web of Science ®Google Scholar
• Choudhary M, Ismail EN, Yao P-L, et al. LXRs regulate features of age-related macular degeneration and may be a potential therapeutic target. JCI Insight. 2020;5(1):131928.
   PubMed Web of Science ®Google Scholar
• Lai YS, Yang TC, Chang PY, et al. Electronegative LDL is linked to high-fat, high-cholesterol dietinduced nonalcoholic steatohepatitis in hamsters. J Nutr Biochem. 2016;30:44–52.
   PubMed Web of Science ®Google Scholar
• Akheruzzaman M, Hegde V, Shin AC, et al. Reducing endogenous insulin is linked with protection against hepatic steatosis in mice. Nut Diabetes. 2020;10(1):11.
   Google Scholar
• Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis. 2015;35(3):270–290.
   PubMed Web of Science ®Google Scholar
• Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Clin Pract Gastroenterol Hepatol. 2019;16(7):411–428.
   Google Scholar
• Carlsson B, Lindén D, Brolén G, et al. Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305–1320.
   PubMed Web of Science ®Google Scholar
• Bruschi FV, Tardelli M, Claudel T, et al. PNPLA3 expression and its impact on the liver current perspectives. Hepat Med. 2017;6:55–66.
   Google Scholar
• Basantani MK, Sitnick MT, Cai L, et al. PNPLA3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J Lipid Res. 2011;52(2):318–329.
   PubMed Web of Science ®Google Scholar
• Chen W, Chang B, Li L, et al. Patatin-like phospholipase domaincontaining3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology. 2010;52(3):1134–1142.
   PubMed Web of Science ®Google Scholar
• He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285(9):6706–6715.
   PubMed Web of Science ®Google Scholar
• Merino DM, Johnston H, Clarke S, et al. Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults. Mol Genet Metab. 2011;103(2):171–178.
   PubMed Web of Science ®Google Scholar
• Lattka E, Eggers S, Moeller G, et al. A common FADS2 promoter polymorphism increases promoter activity and facilitates binding of transcription factor ELK1. J Lipid Res. 2010;51(1):182–191.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu S, Gao Y, et al. Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. BMC Biochem. 2019;20(1):3.
   PubMedGoogle Scholar
• Cai W, Weng D-H, Yan P, et al. Genetic polymorphisms associated with nonalcoholic fatty liver disease in Uyghur population: a case-control study and meta-analysis. Lipids Health Dis. 2019;18(1):14.
   PubMedGoogle Scholar
• Wang C, Gong J, Wu H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease. Biomed Rep. 2017;7(2):95–104.
   PubMed Web of Science ®Google Scholar
• de Meneses Fujii TM, Norde MM, Fisberg RM, et al. FADS1 and ELOVL2 polymorphisms reveal associations for differences in lipid metabolism in a cross-sectional populationbased survey of Brazilian men and women. Nut Res. 2020;78:42–49.
   PubMed Web of Science ®Google Scholar
• Ghazalpour A, Cespedes I, Bennett BJ, et al. Expanding role of gut microbiota in lipid metabolism. Curr Opin Lipidol. 2016;27(2):141–147.
   PubMed Web of Science ®Google Scholar
• Schloig S, Arumugam M, Sunagawa S, et al. Genomic variation landscape of the human gut microbiome. Nature. 2013;493(7430):45–50.
   PubMed Web of Science ®Google Scholar
• Devillard E, McIntosh FM, Duncan SH, et al. Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid. J Bacteriol. 2007;189(6):2566–2570.
   PubMed Web of Science ®Google Scholar
• Li X, Li C. Analysis of changes in intestinal flora and intravascular inflammation and coronary heart disease in obese patients. Exp Ther Med. 2018;15(5):4538–4542.
   PubMed Web of Science ®Google Scholar
• Li CY, Dempsey JL, Wang D, et al. PBDEs altered gut microbiome and bile acid homeostasis in male C57BL/6 mice. Drug Metab Dispos. 2018;46(8):1226–1240.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–1685.
   PubMed Web of Science ®Google Scholar
• Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13(3):193–204.
   PubMed Web of Science ®Google Scholar
• Liu Q, Liu S, Chen L, et al. Role an effective therapeutic target of gut microbiota I NAFLD/NASH (Review). Exp Ther Med. 2019;18(3):1935–1944.
   PubMed Web of Science ®Google Scholar
• Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787–1794.
   PubMed Web of Science ®Google Scholar
• Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci. 2004;101(44):15718–15723.
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, et al. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology. 2020;158(7):1881–1898.
   PubMed Web of Science ®Google Scholar
• Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 2019;76(8):1541–1558.
   PubMed Web of Science ®Google Scholar
• Chiu -C-C, Ching Y-H, Li Y-P, et al. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients. 2017;9(11):1220.
   Web of Science ®Google Scholar
• Perdomo CM, Frühbeck G. Escalada j.impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients. 2019;11(3):677.
   Web of Science ®Google Scholar
• Berná G, Romero-Gomez M. The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management. Liver Int. 2020;40(1):102–108.
   PubMedGoogle Scholar
• Sánchez-Tapia M, Tovar AR, Torres N. Diet as regulator of gut microbiota and its role in health and disease. Arch Med Res. 2019;50(5):259–268.
   PubMed Web of Science ®Google Scholar
• Wit NJW, Afman LA, Mensink M, et al. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol. 2012;57(6):1370–1373.
   PubMed Web of Science ®Google Scholar
• Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: evidence and plausible mechanisms. Liver Int. 2017;37(7):936–949.
   PubMed Web of Science ®Google Scholar
• Schwingshackl L, Strasser B, Hoffmann G. Effects of monounsaturated fatty acids on glycaemic control in patients with abnormal glucose metabolism: A systematic review and meta-analysis. Ann Nutr Metab. 2011;58(4):290–296.
   PubMed Web of Science ®Google Scholar
• López-Miranda J, Pérez-Jiménez F, Ros E, et al. Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain). Nutr Metab Cardiovasc Dis. 2010;20(4):284–294.
   PubMed Web of Science ®Google Scholar
• Tsunoda N, Ikemoto S, Takahashi M, et al. High-monounsaturated fat diet-induced obesity and diabetes in C57BL/6J mice. Metabolism. 1998;47(6):724–730.
   PubMed Web of Science ®Google Scholar
• Hadi E, Zahra Y, Hossein F, et al. Differential effects of dietary fatty acids on body composition and adiposity. Curr Nutri Food Sci. 2020;16(2):142–154.
   Web of Science ®Google Scholar
• Li X, Sun R, Liu R. Natural products in Licorice for the therapy of liver diseases: progress and future opportunities. Pharmacol Res. 2019;144:210–226.
   PubMed Web of Science ®Google Scholar
• Bagetta D, Maruca A, Lupia A, et al. Mediterranean products as promising source of multi-target agents in the treatment of metabolic syndrome. Eur J Med Chem. 2020;15:111903.
   Google Scholar
• Rosqvist F, Kullberg J, Ståhlman M, et al. Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: A randomized trial. J Clin Endocrinol Metab. 2019;104(12):6207–6219.
   PubMed Web of Science ®Google Scholar
• Aglago EK, Huybrechts I, Murphy N, et al. Consumption of fish and long-chain n-3 polyunsaturated fatty acids is associated with reduced risk of colorectal cancer in a large European cohort. Clin Gastroenterol Hepatol. 2020;18(3):654–666.
   PubMed Web of Science ®Google Scholar
• De Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clin Nutr. 2018;37(1):37–55.
   PubMed Web of Science ®Google Scholar
• Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56(8):365–379.
   PubMed Web of Science ®Google Scholar
• Alferink LJ, Kiefte-de Jong JC, Erler NS, et al. Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam study. Gut. 2019;68(6):1088–1098.
   PubMed Web of Science ®Google Scholar
• Tetri LH, Basaranoglu M, Brunt EM, et al. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):987–995.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Ford DA, Acharya S, et al. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. Lipids. 2012;47(10):941–950.
   PubMed Web of Science ®Google Scholar
• Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015;31(1):69–75.
   PubMed Web of Science ®Google Scholar
• Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol. 2019;54(3):209–217.
   PubMed Web of Science ®Google Scholar
• Devkota S, Chang EB. Nutrition, microbiome, and intestinal inflammatrion. Curr Opin Gastroenterol. 2013;29(6):603–607.
   PubMed Web of Science ®Google Scholar
• Sáez-lara MJ, Robles-Sánchez C, Ruiz-ojeda FJ, et al. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: A review of human clinical trials. Int J Mol Sci. 2016;17(6):928.
   Web of Science ®Google Scholar
• Federico A, Dallio M, Godos J, et al. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res. 2016;167(1):116–124.
   PubMed Web of Science ®Google Scholar
• Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–1836.
   PubMed Web of Science ®Google Scholar
• Liu X, Green RM. Beyond FXR to target new therapies for NAFLD. Hepatology. 2017;66(6):1724–1726.
   PubMed Web of Science ®Google Scholar
• Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585.
   PubMed Web of Science ®Google Scholar
• Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(1):49–60.
   PubMed Web of Science ®Google Scholar
• Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63.
   PubMed Web of Science ®Google Scholar
• Shih DM, Wang Z, Lee R, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res. 2015;56(1):22–37.
   PubMed Web of Science ®Google Scholar
• Warrier M, Shih DM, Burrows AC, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 2015;10(3):326–338.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Gianotti TF, Burgueno AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 2013;62:1356–1363.
   PubMed Web of Science ®Google Scholar
• Yu H-L, Dong S, Gao L-F, et al. Global DNA methylation was changed by a maternal high-lipid, high-energy diet during gestation and lactation in male adult mice liver. Br J Nutr. 2015;113(7):1032–1039.
   PubMed Web of Science ®Google Scholar
• Mathers JC, McKay JA. Epigenetics - potential contribution to fetal programming. Adv Exp Med Biol. 2009;646:119–123.
   PubMed Web of Science ®Google Scholar
• Burdge GC, Lillycrop KA, Acids F. Epigenetics. Curr Opin Clin Nutr Metab Care. 2014;17(2):156–161.
   PubMed Web of Science ®Google Scholar
• Benatti RO, Mello AM, Borges FO, et al. Maternal high-fat diet consumption modulates hepatic lipid metabolism and microRNA-122 (miR-122) and microRNA-370 (miR-370) expression in offspring. Br J Nutr. 2014;111(12):2112–2122.
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhang Q, Mul JD. Maternal high-calorie diet is associated with altered hepatic microRNA expression and impaired metabolic health in offspring at weaning age. Endocrine. . 2016;54(1):70–80.
   PubMed Web of Science ®Google Scholar
• Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development. 2007;134(22):3959–3965.
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38.
   PubMed Web of Science ®Google Scholar
• Merlo A, Herman JG, Mao L, et al. 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1(7):686–692.
   PubMed Web of Science ®Google Scholar
• Choi SW, Epigenetics FS, New A. Bridge between nutrition and health. Adv Nutr. 2010;1(1):8–16.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim Y, Friso S, et al. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2017;54:78–88.
   PubMed Web of Science ®Google Scholar
• Mann DA. Epigenetics in liver disease. Hepatology. 2014;60(4):1418–1425.
   PubMed Web of Science ®Google Scholar
• Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics.  Gut. 2016;65(11):1895–1905.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Fernández Gianotti T, Castaño GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–812.
   PubMed Web of Science ®Google Scholar
• Lee JH, Friso S, Choi SW. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients. 2014;6(8):3025–3303.
   Web of Science ®Google Scholar
• Park LK, Friso S, Choi SW. Nutritional influences on epigenetics and age-related disease. Proc Nutr Soc. 2012;71(1):75–83.
   PubMed Web of Science ®Google Scholar
• da Silva RP, Kelly KB, Al Rajabi A, et al. Novel insights on interactions between folate and lipid metabolism. Biofactors. 2014;40(3):277–283.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Zhang HW, Zhou JY, et al. Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. J Nutr Biochem. 2014;25(3):329–336.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Rosselli MS, Gemma C, et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology. 2010;52(6):1992–2000.
   PubMed Web of Science ®Google Scholar
• Murphy SK, Yang H, Moylan CA, et al. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(5):1076–1087.
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Han T, Fuscoe JC, et al. Status of hepatic DNA methylome predetermines and modulates the severity of non-alcoholic fatty liver injury in mice. BMC Genomics. 2016;17:298.
   PubMed Web of Science ®Google Scholar
• Gerhard GS, Malenica I, Llaci L, et al. Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways. Clin Epigenetics. 2018;10(1):93.
   PubMedGoogle Scholar
• Chen ZJ, Pikaard CS. Epigenetic silencing of RNA polymerase I transcription: a role for DNA methylation and histone modification in nucleolar dominance. Genes Dev. 1997;11(16):2124–2136.
   PubMed Web of Science ®Google Scholar
• Gallego-Durán R, Romero-Gómez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: an emerging field. World J Hepatol. 2015;7(24):2497–2502.
   PubMed Web of Science ®Google Scholar
• Granger A, Abdullah I, Huebner F, et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. Faseb J. 2008;22(10):3549–3560.
   PubMed Web of Science ®Google Scholar
• Chung MY, Song JH, Lee J, et al. Tannic acid, a novel histone acetyltransferase inhibitor, prevents non-alcoholic fatty liver disease both in vivo and in vitro model. Mol Metab. 2019;19:34–48.
   PubMed Web of Science ®Google Scholar
• Tian Y, Wong VW, Chan HL, et al. Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin Cancer Biol. 2013;23(6 Pt B):471–482.
   PubMed Web of Science ®Google Scholar
• Cai C, Yu H, Huang G, et al. Histone modifications in fatty acid synthase modulated by carbohydrate responsive element binding protein are associated with nonalcoholic fatty liver disease. Int J Mol Med. 2018;42(3):1215–1228.
   PubMed Web of Science ®Google Scholar
• Du X, Cai C, Yao J, et al. Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD. Biochem Biophys Res Commun. 2017;483(1):409–417.
   PubMed Web of Science ®Google Scholar
• Feng D, Liu T, Sun Z, et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science. 2011;331(6022):1315–1319.
   PubMed Web of Science ®Google Scholar
• Sun Z, Miller RA, Patel RT, et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med. 2012;18(6):934–942.
   PubMed Web of Science ®Google Scholar
• Colak Y, Ozturk O, Senates E, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit. 2011;17(5):HY5–HY9.
   PubMed Web of Science ®Google Scholar
• Li F, Li H, Jin X, et al. Adipose-specific knockdown of Sirt1 results in obesity and insulin resistance by promoting exosomes release. Cell Cycle. 2019;18(17):2067–2082.
   PubMed Web of Science ®Google Scholar
• Suter MA, Chen A, Burdine MS, et al. A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. Faseb J. 2012;26(12):5106–5114.
   PubMed Web of Science ®Google Scholar
• Cao Y, Xue Y, Xue L, et al. Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation. J Hepatol. 2013;59(6):1299–1306.
   PubMed Web of Science ®Google Scholar
• van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6(7):851–864.
   PubMed Web of Science ®Google Scholar
• Loosen SH, Schueller F, Trautwein C, et al. Role of circulating microRNAs in liver diseases. World J Hepatol. 2017;9(12):586–594.
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–355.
   PubMed Web of Science ®Google Scholar
• Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014;51(4):759–774.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Rathbone MJ, Hansbro PM, et al. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology. Drug Deliv Transl Res. 2018;8(1):97–110.
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524.
   PubMed Web of Science ®Google Scholar
• Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014;13(8):622–638.
   PubMed Web of Science ®Google Scholar
• Erson-Bensan AE. Introduction to microRNAs in biological systems. Methods Mol Biol. 2014;1107:1–14.
   PubMedGoogle Scholar
• Berezikov E, Chung WJ, Willis J, et al. Mammalian mirtron genes. Mol Cell. 2007 Oct 26;28(2):328–336.
   PubMed Web of Science ®Google Scholar
• Okamura K, Hagen JW, Duan H, et al. The mirtron pathway generates microRNA-class regulatory RNAs in drosophila. Cell. 2007;130(1):89–100.
   PubMed Web of Science ®Google Scholar
• Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature. 2007;448(7149):83–86.
   Google Scholar
• Simonson B, Das S. MicroRNA therapeutics: the next magic bullet? Mini Rev Med Chem. 2015;15(6):467–474.
   PubMed Web of Science ®Google Scholar
• Jiang X, Tsitsiou E, Herrick SE, et al. MicroRNAs and the regulation of fibrosis. Febs J. 2010;277(9):2015–2021.
   PubMed Web of Science ®Google Scholar
• Guo CJ, Pan Q, Li DG, et al. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J Hepatol. 2009;50(4):766–778.
   PubMed Web of Science ®Google Scholar
• Guo CJ, Pan Q, Xiong H, et al. Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension? Biomed Res Int. 2014;2014:797898.
   PubMed Web of Science ®Google Scholar
• Akbari Moqadam F, Pieters R, den Boer ML. The hunting of targets: challenge in miRNA research. Leukemia. 2013;27(1):16–23.
   PubMed Web of Science ®Google Scholar
• Laganà A. Computational prediction of microRNA targets. Adv Exp Med Biol. 2015;887:231–252.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Meroni M, Longo M, et al. miRNA signature in NAFLD: A turning point for a non-invasive diagnosis. Int J Mol Sci. 2018;19(12):pii: E3966.
   Web of Science ®Google Scholar
• Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10(9):542–552.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar
• Schmidt MF. Drug target miRNAs: chances and challenges. Trends Biotechnol. 2014;32(11):578–585.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen T, Tong W. miRNAs and their application in drug-induced liver injury. Biomark Med. 2014;8(2):161–172.
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn. 2015;15(9):1159–1169.
   PubMed Web of Science ®Google Scholar
• Sobolewski C, Calo N, Portius D, et al. MicroRNAs in fatty liver disease. Semin Liver Dis. 2015;35(1):12–25.
   PubMed Web of Science ®Google Scholar
• Huan L, Liang LH, He XH. Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med. 2016 Dec;13(4):407–425.
   PubMed Web of Science ®Google Scholar
• Del Campo JA, Gallego-Durán R, Gallego P, et al., Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci. 2018;19(3): pii: E911.
   PubMed Web of Science ®Google Scholar
• Takaki Y, Saito Y, Takasugi A, et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis. Cancer Sci. 2014;105(10):1254–1260.
   PubMed Web of Science ®Google Scholar
• Li ZY, Xi Y, Zhu WN, et al. Positive regulation of hepatic miR-122 expression by HNF4a. J Hepatol. 2011;55(3):602–611.
   PubMed Web of Science ®Google Scholar
• Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103.
   PubMed Web of Science ®Google Scholar
• Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6(8):e23937.
   PubMed Web of Science ®Google Scholar
• Zheng L, Lv GC, Sheng J, et al. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-α expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol. 2010;25(1):156–163.
   PubMed Web of Science ®Google Scholar
• Sun C, Fan J-G QL. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci. 2015;16(3):5161–5179.
   PubMed Web of Science ®Google Scholar
• Tryndyak VP, Latendresse JR, Montgomery B, et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol. 2012;262(1):52–59.
   PubMed Web of Science ®Google Scholar
• Quinn J, Chang H. Unique features of long non-coding RNA biogenesis and function. Nat Rev. 2016;17(1):47–62.
   Google Scholar
• Marchese F, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18(1):206.
   PubMed Web of Science ®Google Scholar
• Dhanoa J, Sethi R, Verma R, et al. Long non-coding RNA: its evolutionary relics and biological implications in mammals: a review. J Animal Sci Technol. 2018;60:25.
   PubMed Web of Science ®Google Scholar
• Mishra K, Kanduri C. Understanding long noncoding RNA and chromatin interactions: what we know so far. Noncoding RNA. 2019;5(4):54.
   PubMed Web of Science ®Google Scholar
• Sun C, Liu X, Yi Z, et al. Genome-wide analysis of long noncoding RNA expression profiles in patients with non-alcoholic fatty liver disease. Int Univ Biochem Mol Biol. 2015;67(11):847–852.
   Google Scholar
• Chen Y, Huang H, Xu C, et al. Long non-coding RNA profiling in a non-alcoholic fatty liver disease rodent model: new insight into pathogenesis. Int J Mol Sci. 2017;18(1):21.
   Web of Science ®Google Scholar
• Chen X, Xu Y, Zhao D, et al. LncRNA-AK012226 Is involved in fat accumulation in db/db mice fatty liver and non-alcoholic fatty liver disease cell model. Front Pharmacol. 2018;9:888.
   PubMed Web of Science ®Google Scholar
• Shen X, Guo H, Xu J, et al. Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease. J Cell Physiol. 2019;234(10):18169-18179.
   Web of Science ®Google Scholar
• Wang X. Down-regulation of lncRNA-NEAT1 alleviated the non-alcoholic fatty liver disease via mTOR/S6K1 signaling pathway. J Cell Biochem. 2018;119(2):1567–1574.
   PubMed Web of Science ®Google Scholar
• Wang H, Cao Y, Shu L, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med. 2020;24(2):1399–1412.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang J, Li H, et al. LncRNA Gm12664–001 ameliorates nonalcoholic fatty liver through modulating miR-295-5p and CAV1 expression. Nutri Metabol. 2020;17:13.
   PubMed Web of Science ®Google Scholar
• Liu F, Chen Q, Chen F, et al. The lncRNA ENST00000608794 acts as a competing endogenous RNA to regulate PDK4 expression by sponging miR-15b-5p in dexamethasone induced steatosis. BBA – Mol Cell Bio of Lipids. 2019;1864(10):1449–1457.
   PubMedGoogle Scholar
• Sun Y, Song Y, Liu C, et al. LncRNA NEAT1-microRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling. Biochem Biophys Res Commun. 2019;516(2):584–590.
   PubMed Web of Science ®Google Scholar
• Zhang LH, Li D, Li D, et al. Long noncoding RNA mirt2 upregulates USP10 expression to suppress hepatic steatosis by sponging miR-34a-5p. Gene. 2019;700:139–148.
   PubMed Web of Science ®Google Scholar